CEACAM5 and neoplasm: BC biomarkers (glycoproteins: mucin 1 (MUC1), HER2, carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), carbohydrate antigen 15-3 (CA15-3), CA 27-29, mammaglobin (MAM); DNA: BRCA1, BRCA2, proteins: Ki-67, OPN, microRNAs, and circulating tumor cells (CTC)) can be classified as diagnostic (healthy versus BC), prognostic (early BC versus advanced BC), predictive (provide information regarding whether a particular treatment will be beneficial for the BC patient) or therapeutic (a target biomolecule for therapeutics) based biomarkers [30,31].